LEXINGTON, Mass., April 28,
2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS),
a biotechnology company focused on the development of innovative
therapeutics for the treatment of cancer, today announced that the
Company will release its first quarter 2022 financial results on
Thursday, May 5, 2022, after the
close of U.S. markets. Management will host a conference call on
the same day at 4:30 pm ET.
To access the live conference call, please dial (888) 346-6389
from the United States or (412) 317- 5252 from other
locations, shortly before 4:30 pm ET. The conference call can
also be accessed on the Curis website at www.curis.com in
the 'Investors' section. A replay of the financial results
conference call will be available on the Curis website shortly
after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is
currently undergoing testing in the Phase 1/2 TakeAim Lymphoma
trial, in patients with hematologic malignancies, such as
non-Hodgkins lymphoma and other B cell malignancies, both as a
monotherapy and in combination with BTK inhibitor ibrutinib, and
the Phase 1/2 TakeAim Leukemia trial in patients with acute myeloid
leukemia and myelodysplastic syndrome, for which it has received
Orphan Drug Designation from the U.S. Food and Drug Administration.
The FDA has placed a partial clinical hold on the TakeAim Lymphoma
and TakeAim Leukemia trials during which no new patients will be
enrolled, and current study participants benefiting from treatment
may continue to be treated with emavusertib at doses of 300mg BID
or lower. In addition, Curis is engaged in a collaboration with
ImmuNext for development of CI-8993, a monoclonal anti-VISTA
antibody, which is currently undergoing testing in a Phase 1 trial
in patients with solid tumors. Curis is also party to a
collaboration with Genentech, a member of the Roche Group, under
which Genentech and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis's website at www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-release-first-quarter-2022-financial-results-and-hold-conference-call-on-may-5-2022-301535826.html
SOURCE Curis, Inc.